N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US-10259810-B2 · Apr 16, 2019 · US
N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10647717B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10647717-B2 |
| Application number | US-201916444495-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2019 |
| Priority date | Oct 9, 2015 |
| Publication date | May 12, 2020 |
| Grant date | May 12, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
First claim
Opening claim text (preview).
We claim: 1. A compound, which is wherein one or more hydrogen atoms are replaced by tritium; or a pharmaceutically acceptable salt thereof. 2. A compound, which is wherein one or more oxygen atoms are replaced by 15 O; or a pharmaceutically acceptable salt thereof. 3. A compound, which is wherein one or more carbon atoms are replaced by 11 C; or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
- Akkari Rhalid
- Alvey Luke Jonathan
- Bock Xavier Marie
- Brown Brian S
- Claes Pieter Isabelle Roger
- Cowart Marlon D
- De Lemos Elsa
- Desroy Nicolas
- Duthion Béranger
- Gfesser Gregory A
- Gosmini Romain Luc Marie
- Housseman Christopher Gaëtan
- Jansen Koen Karel
- Ji Jianguo
- Kym Philip R
- Lefrancois Jean-Michel
- Mammoliti Oscar
- Menet Christel Jeanne Marie
- Merayo Merayo Nuria
- Newsome Gregory John Robert
- Palisse Adeline Marie Elise
- Patel Sachin V
- Pizzonero Matthieu Rafaël
- Shrestha Anurupa
- Swift Elizabeth C
- Van Der Plas Steven Emiel
- Wang Xueqing
- De Blieck Ann
Classifications
Artificial tears; Irrigation solutions · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
not condensed and containing further heterocyclic rings · CPC title
for pancreatic disorders, e.g. pancreatic enzymes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10647717B2 cover?
- The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic ins…
- Who is the assignee on this patent?
- Abbvie Sarl, Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).